Literature DB >> 17636423

A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families.

Patricia N Tonin1, Christine M Maugard, Chantal Perret, Anne-Marie Mes-Masson, Diane M Provencher.   

Abstract

Pathogenic mutations in BRCA1 and BRCA2 have been reported in about 55-59% of breast and ovarian cancer (HBOC) families of French Canadian descent, where about 70% of families with more than two cases of ovarian cancer were mutation-positive. Given that specific subtypes of ovarian cancer are associated with mutation-positive families, we reviewed the features of 54 HBOC families of French Canadian descent that had histopathologically confirmed cases of invasive ovarian cancer where the BRCA1 and BRCA2 mutation status is known, and 27 families harbored germline mutations. The number of cases and ages of diagnosis of either breast cancers or ovarian cancers did not differ significantly in comparisons of mutation-positive and mutation-negative groups. However, the distribution of histopathological subtypes for the 79 cases of invasive epithelial cancer from the 54 HBOC families differed when grouped according to familial mutation status. The mutation-negative group had significantly more cases of the mucinous subtype of ovarian cancer when compared with the BRCA1 (P = 0.005) and BRCA2 (P = 0.017) mutation-positive groups. The presence of a mucinous subtype ovarian cancer in multiple young age of onset breast and/or ovarian mutation-negative HBOC cancer families warrants further investigation, as these families appear to exhibit features most consistent with BRCA1 and BRCA2 carrier status.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17636423     DOI: 10.1007/s10689-007-9152-x

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  24 in total

1.  Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer families.

Authors:  A P Manning; D Abelovich; P Ghadirian; J A Lambert; D Frappier; D Provencher; A Robidoux; T Peretz; S A Narod; A M Mes-Masson; W D Foulkes; T Wang; K Morgan; T M Fujiwara; P N Tonin
Journal:  Hum Hered       Date:  2001       Impact factor: 0.444

Review 2.  Hereditary ovarian cancer.

Authors:  Jaime Prat; Adriana Ribé; Alberto Gallardo
Journal:  Hum Pathol       Date:  2005-08       Impact factor: 3.466

Review 3.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

4.  Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families.

Authors:  Hélène Vézina; Francine Durocher; Martine Dumont; Louis Houde; Csilla Szabo; Martine Tranchant; Jocelyne Chiquette; Marie Plante; Rachel Laframboise; Jean Lépine; Heli Nevanlinna; Dominique Stoppa-Lyonnet; David Goldgar; Peter Bridge; Jacques Simard
Journal:  Hum Genet       Date:  2005-05-10       Impact factor: 4.132

Review 5.  Population history and its impact on medical genetics in Quebec.

Authors:  A-M Laberge; J Michaud; A Richter; E Lemyre; M Lambert; B Brais; G A Mitchell
Journal:  Clin Genet       Date:  2005-10       Impact factor: 4.438

Review 6.  Models of genetic susceptibility to breast cancer.

Authors:  A C Antoniou; D F Easton
Journal:  Oncogene       Date:  2006-09-25       Impact factor: 9.867

7.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

8.  Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer.

Authors:  Jacques Simard; Martine Dumont; Anne-Marie Moisan; Valérie Gaborieau; Hélène Malouin; Francine Durocher; Jocelyne Chiquette; Marie Plante; Denise Avard; Paul Bessette; Claire Brousseau; Michel Dorval; Béatrice Godard; Louis Houde; Yann Joly; Marie-Andrée Lajoie; Gilles Leblanc; Jean Lépine; Bernard Lespérance; Hélène Vézina; Jillian Parboosingh; Roxane Pichette; Louise Provencher; Josée Rhéaume; Daniel Sinnett; Carolle Samson; Jean-Claude Simard; Martine Tranchant; Patricia Voyer; Douglas Easton; Sean V Tavtigian; Bartha-Maria Knoppers; Rachel Laframboise; Peter Bridge; David Goldgar
Journal:  J Med Genet       Date:  2006-08-11       Impact factor: 6.318

9.  A genome wide linkage search for breast cancer susceptibility genes.

Authors:  Paula Smith; Lesley McGuffog; Douglas F Easton; Graham J Mann; Gulietta M Pupo; Beth Newman; Georgia Chenevix-Trench; Csilla Szabo; Melissa Southey; Hélène Renard; Fabrice Odefrey; Henry Lynch; Dominique Stoppa-Lyonnet; Fergus Couch; John L Hopper; Graham G Giles; Margaret R E McCredie; Saundra Buys; Irene Andrulis; Ruby Senie; David E Goldgar; Rogier Oldenburg; Karin Kroeze-Jansema; Jaennelle Kraan; Hanne Meijers-Heijboer; Jan G M Klijn; Christi van Asperen; Inge van Leeuwen; Hans F A Vasen; Cees J Cornelisse; Peter Devilee; Linda Baskcomb; Sheila Seal; Rita Barfoot; Jon Mangion; Anita Hall; Sarah Edkins; Elizabeth Rapley; Richard Wooster; Jenny Chang-Claude; Diana Eccles; D Gareth Evans; P Andrew Futreal; Katherine L Nathanson; Barbara L Weber; Nazneen Rahman; Michael R Stratton
Journal:  Genes Chromosomes Cancer       Date:  2006-07       Impact factor: 5.006

10.  BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.

Authors:  Antonis C Antoniou; Francine Durocher; Paula Smith; Jacques Simard; Douglas F Easton
Journal:  Breast Cancer Res       Date:  2005-12-12       Impact factor: 6.466

View more
  11 in total

Review 1.  Unmasking the complexities of mucinous ovarian carcinoma.

Authors:  Michael Frumovitz; Kathleen M Schmeler; Anais Malpica; Anil K Sood; David M Gershenson
Journal:  Gynecol Oncol       Date:  2010-03-23       Impact factor: 5.482

2.  Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype.

Authors:  Mika Fujiwara; Valerie A McGuire; Anna Felberg; Weiva Sieh; Alice S Whittemore; Teri A Longacre
Journal:  Am J Surg Pathol       Date:  2012-08       Impact factor: 6.394

3.  Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer.

Authors:  Luca Cavallone; Suzanna L Arcand; Christine M Maugard; Serge Nolet; Louis A Gaboury; Anne-Marie Mes-Masson; Parviz Ghadirian; Diane Provencher; Patricia N Tonin
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

Review 4.  Mucinous tumors of the ovary: current thoughts on diagnosis and management.

Authors:  Jubilee Brown; Michael Frumovitz
Journal:  Curr Oncol Rep       Date:  2014-06       Impact factor: 5.075

5.  Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.

Authors:  Andrew D Spearman; Kevin Sweet; Xiao-Ping Zhou; Jane McLennan; Fergus J Couch; Amanda Ewart Toland
Journal:  J Clin Oncol       Date:  2008-09-29       Impact factor: 44.544

6.  Acceptance of genetic counseling and testing in a hospital-based series of patients with gynecological cancer.

Authors:  Nicky Dekker; Eleonora B L van Dorst; Rob B van der Luijt; Marielle E van Gijn; Marc van Tuil; Johan A Offerhaus; Margreet G E M Ausems
Journal:  J Genet Couns       Date:  2012-11-30       Impact factor: 2.537

7.  A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.

Authors:  Moria H Belanger; Lena Dolman; Suzanna L Arcand; Zhen Shen; George Chong; Anne-Marie Mes-Masson; Diane Provencher; Patricia N Tonin
Journal:  J Ovarian Res       Date:  2015-03-27       Impact factor: 4.234

8.  Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease.

Authors:  Hubert Fleury; Laudine Communal; Euridice Carmona; Lise Portelance; Suzanna L Arcand; Kurosh Rahimi; Patricia N Tonin; Diane Provencher; Anne-Marie Mes-Masson
Journal:  Genes Cancer       Date:  2015-09

9.  Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.

Authors:  Cécile Le Page; Kurosh Rahimi; Martin Köbel; Patricia N Tonin; Liliane Meunier; Lise Portelance; Monique Bernard; Brad H Nelson; Marcus Q Bernardini; John M S Bartlett; Dimcho Bachvarov; Walter H Gotlieb; Blake Gilks; Jessica N McAlpine; Mark W Nachtigal; Alain Piché; Peter H Watson; Barbara Vanderhyden; David G Huntsman; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  BMC Cancer       Date:  2018-03-27       Impact factor: 4.430

10.  BRCA1 founder mutations and beyond in the Polish population: A single-institution BRCA1/2 next-generation sequencing study.

Authors:  Artur Kowalik; Monika Siołek; Janusz Kopczyński; Kamila Krawiec; Joanna Kalisz; Sebastian Zięba; Beata Kozak-Klonowska; Elżbieta Wypiórkiewicz; Jowita Furmańczyk; Ewelina Nowak-Ozimek; Małgorzata Chłopek; Paweł Macek; Jolanta Smok-Kalwat; Stanisław Góźdź
Journal:  PLoS One       Date:  2018-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.